Colorectal Cancer Patient Characteristics, Treatment and Survival in Oman - a Single Center Study

  • Kumar, Shiyam (Department of Medicine, Sultan Qaboos University Hospital) ;
  • Burney, Ikram A (Department of Medicine, Sultan Qaboos University Hospital) ;
  • Zahid, Khawaja Farhan (Department of Medicine, Sultan Qaboos University Hospital) ;
  • Souza, Philomena Charlotte D (Nursing Directorate, Sultan Qaboos University Hospital) ;
  • Belushi, Muna AL (Nursing Directorate, Sultan Qaboos University Hospital) ;
  • Mufti, Taha Dawood (Department of Medicine, Sultan Qaboos University Hospital) ;
  • Meki, Waeil AL (Department of Medicine, Sultan Qaboos University Hospital) ;
  • Furrukh, Muhammad (Department of Medicine, Sultan Qaboos University Hospital) ;
  • Moundhri, Mansour S AL (College of Medicine and Health Sciences, Sultan Qaboos University)
  • Published : 2015.07.13


Background: Colorectal cancer is the most common gastrointestinal cancer in Oman with an increasing incidence. We here report the presenting features, treatment outcomes and survival in a University hospital in Oman and compare our data with regional and international studies. Materials and Methods: Medical records of patients with colorectal cancer were reviewed retrospectively between June 2000 and December 2013 and were followed until June 2014. Results: A total of 162 patients were diagnosed with colorectal cancer. The majority were males (58.6%), with a median age of 56 years. Rectum was involved in 29.6% of patients, followed by ascending and sigmoid colon. The majority of patients had stage III (42.6%) and stage IV (32.7%) disease at presentation. K-Ras status was checked for 79 patients, and 41 (51.9%) featured the wild type. Median relapse free survival was 22 months. Median overall survival for all patients was 43 months. Observed 5 year overall survival (OS) for stages I, II and III was 100%, 60% and 60% respectively. On Log rank univariate analysis, age, BMI, diabetes, hypertension, metformin use, stage, clinical nodal status for rectal cancer, pathological T and nodal status, site of metastasis, surgical intervention, chemotherapy, radiotherapy, chemotherapy regimen, no of cycles of chemotherapy, response, RFS, site of recurrence and administration of $2^{nd}$ line chemotherapy were significant factors affecting OS. On Cox regression multivariate analysis none of the factors independently affected the OS. Conclusions: The majority of patients present with advanced disease and at young age. The survival rates are comparable to the published regional and international literature.


Chemotherapy;olon cancer;metastasis;recurrence;Oman


  1. Al-Ahwal MS, Shafik YH, HM A-A (2013). First national survival data for colorectal cancer among Saudis between 1994 and 2004: what's next? BMC Public Health, 13, 73.
  2. Al-Shamsi SR, Bener A, Al-Sharhant M, et al (2003). Clinicopathological pattern of colorectal cancer in the United Arab Emirates. Saudi Med J, 24, 518-22.
  3. Aljebreen AM (2007). Clinico-pathological patterns of colorectal cancer in Saudi Arabia: younger with an advanced stage presentation. Saudi J Gastroenterol, 13, 84-7.
  4. Alsina J, Choti MA (2011). Liver-directed therapies in colorectal cancer. Semin Oncol, 38, 561-7.
  5. Amin TT, Suleman W, Al Taissan AA, et al (2012). Patients' profile, clinical presentations and histopathological features of colo-rectal cancer in Al Hassa region, Saudi Arabia. Asian Pac J Cancer Prev, 13, 211-6.
  6. Andre T, Boni C, Mounedji-Boudiaf L, et al (2004). Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. New England J Med, 350, 2343-51.
  7. Benson AB, 3rd, Bekaii-Saab T, Chan E, et al (2013). Localized colon cancer, version 3.2013: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw, 11, 519-28.
  8. Bhurgri Y, Khan T, Kayani N, et al (2011). Incidence and current trends of colorectal malignancies in an unscreened, low risk Pakistan population. Asian Pac J Cancer Prev, 12, 703-8.
  9. Bozkurt O, Inanc M, Turkmen E, et al (2014). Clinicopathological characteristics and prognosis of patients according to recurrence time after curative resection for colorectal cancer. Asian Pac J Cancer Prev, 15, 9277-81.
  10. Center MM, Jemal A, Smith RA, et al (2009). Worldwide variations in colorectal cancer. A Cancer J Clin, 59, 366-78.
  11. Chen LK, Hwang SJ, Li AF, et al (2001). Colorectal cancer in patients 20 years old or less in Taiwan. South Med J, 94, 1202-5.
  12. Chiu J, Tang V, Leung R, et al (2013). Efficacy and tolerability of adjuvant oral capecitabine plus intravenous oxaliplatin (XELOX) in Asian patients with colorectal cancer: 4-year analysis. Asian Pac J Cancer Prev, 14, 6585-90.
  13. Ciccolallo L, Capocaccia R, Coleman MP, et al (2005). Survival differences between European and US patients with colorectal cancer: role of stage at diagnosis and surgery. Gut, 54, 268-73.
  14. Duran AO, Karaca H, Besiroglu M, et al (2014). XELOX plus bevacizumab vs. FOLFIRI plus bevacizumab treatment for first-line chemotherapy in metastatic colon cancer: a retrospective study of the anatolian society of medical oncology. Asian Pac J Cancer Prev, 15, 10375-9.
  15. El-Bolkainy TN, Sakr MA, Nouh AA, et al (2006 Sep). A comparative study of rectal and colonic carcinoma: demographic, pathologic and TNM staging analysis. J Egypt Natl Canc Inst, 18, 258-63.
  16. Elmunzer BJ, Hayward RA, Schoenfeld PS, et al (2012). Effect of flexible sigmoidoscopy-based screening on incidence and mortality of colorectal cancer: a systematic review and meta-analysis of randomized controlled trials. PLoS Med, 9, 1001352.
  17. Ferlay J, Shin HR, Bray F, et al (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer, 127, 2893-917.
  18. Gatta G, Capocaccia R, Sant M, et al (2000). Understanding variations in survival for colorectal cancer in Europe: a EUROCARE high resolution study. Gut, 47, 533-8.
  19. Hajmanoochehri F, Asefzadeh S, Kazemifar AM, et al (2014). Clinicopathological features of colon adenocarcinoma in Qazvin, Iran: a 16 year study. Asian Pac J Cancer Prev, 15, 951-5.
  20. Hassan AS, Naicker M, Yusof KH, et al (2015). Prognostic factors and the role of adjuvant chemotherapy in post-curative surgery for dukes B and C colon cancers and survival outcomes: a malaysian experience. Asian Pac J Cancer Prev, 16, 2237-43.
  21. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. Ca: A Cancer J Clin, 61, 69-90.
  22. Karnak I, Ciftci AO, Senocak ME, et al (1999). Colorectal carcinoma in children. J Pediatr Surg, 34, 1499-504.
  23. Khurshed A, Ahmed R, Y. B (2007 Oct-Dec). Primary gastrointestinal malignancies in childhood and adolescence--an Asian perspective. Asian Pac J Cancer Prev, 8, 613-7.
  24. Kucukzeybek Y, Dirican A, Demir L, et al (2015). Adjuvant chemotherapy and prognostic factors in stage II colon cancer-izmir oncology group study. Asian Pac J Cancer Prev, 16, 2413.
  25. Labianca R, Nordlinger B, Beretta GD, et al (2010). Primary colon cancer: ESMO Clinical Practice Guidelines for diagnosis, adjuvant treatment and follow-up. Ann Oncol, 21, 70-7.
  26. Lopez-Abente G, Ardanaz E, Torrella-Ramos A, et al (2010). Changes in colorectal cancer incidence and mortality trends in Spain. Ann Oncol, 21, 76-82.
  27. Magaji BA, Moy FM, Roslani AC, et al (2014). Descriptive epidemiology of colorectal cancer in University Malaya Medical Centre, 2001 to 2010. Asian Pac J Cancer Prevention, 15, 6059-64.
  28. Mahdavinia M, Bishehsari F, Ansari R, et al (2005). Family history of colorectal cancer in Iran. BMC Cancer, 5, 112.
  29. McClements PL, Madurasinghe V, Thomson CS, et al (2012). Impact of the UK colorectal cancer screening pilot studies on incidence, stage distribution and mortality trends. Cancer Epidemiol, 36, 232-42.
  30. Nangia-Makker P, Yu Y, Vasudevan A, et al (2014). Metformin: a potential therapeutic agent for recurrent colon cancer. PloS One, 9, 84369.
  31. Nasseri K, Mills PK, M A (2007). Cancer incidence in the middle Eastern population of California, 1988-2004. Asian Pac J Cancer Prev, 8, 405-11.
  32. NCCN. 2014. NCCN Clinical practice guidelines in oncology. Colon cancer version 2.2015 [Online]. National comprehensive cancer network. Available: [Accessed 28/11/2014.
  33. Omranipour R, Mahmoodzadeh H, Safavi F (2014). Prevalence of local recurrence of colorectal cancer at the Iranian cancer institute. Asian Pac J Cancer Prev, 15, 8587-9.
  34. Phipps AI, Scoggins J, Rossing MA, et al (2012). Temporal trends in incidence and mortality rates for colorectal cancer by tumor location: 1975-2007. Am J Public Health, 102, 1791-7.
  35. Ponz de Leon M, Marino M, Benatti P, et al (2004). Trend of incidence, subsite distribution and staging of colorectal neoplasms in the 15-year experience of a specialised cancer registry. Ann Oncol, 15, 940-6.
  36. Rozen P, Rosner G, Liphshitz I, et al (2007). The changing incidence and sites of colorectal cancer in the Israeli Arab population and their clinical implications. Int J Cancer, 120, 147-51.
  37. Ryu SY, Crespi CM, Maxwell AE (2013). Colorectal cancer among Koreans living in South Korea versus California: incidence, mortality, and screening rates. Ethn Health [Epub ahead of print].
  38. Sant M, Allemani C, Santaquilani M, et al (2009). EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999. Results and commentary. Eur J Cancer, 45, 931-91.
  39. Schoen RE, Pinsky PF, Weissfeld JL, et al (2012). Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. N Engl J Med, 366, 2345-57.
  40. Shaikh AJ, Raza S, Shaikh AA, et al (2009 Jul-Sep). Demographics, pathologic patterns and long-term survival in operable colon cancers: local experience in Pakistan. Asian Pac J Cancer Prev, 10, 361-4.
  41. Sultan I, Rodriguez-Galindo C, El-Taani H, et al (2010). Distinct features of colorectal cancer in children and adolescents: a population-based study of 159 cases. Cancer, 116, 758-65.
  42. Tseng C-H (2012). Diabetes, metformin use, and colon cancer: a population-based cohort study in Taiwan. European J Endocrinol, 167, 409-16.
  43. Twelves C, Wong A, Nowacki MP, et al (2005). Capecitabine as adjuvant treatment for stage III colon cancer. New England J Med, 352, 2696-704.
  44. Verdecchia A, Francisci S, Brenner H, et al (2007). Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data. Lancet Oncol, 8, 784-96.
  45. Veruttipong D, Soliman AS, Gilbert SF, et al (2012 Aug). Age distribution, polyps and rectal cancer in the Egyptian population-based cancer registry. World J Gastroenterol, 18, 3997-4003.

Cited by

  1. Application of the Parametric Regression Model with the Four-Parameter Log-Logistic Distribution for Determining of the Effecting Factors on the Survival Rate of Colorectal Cancer Patients in the Presence of Competing Risks vol.19, pp.6, 2017,
  2. Awareness of Stomach and Colorectal Cancer Risk Factors, Symptoms and Time Taken to Seek Medical Help Among Public Attending Primary Care Setting in Muscat Governorate, Oman pp.1543-0154, 2017,